These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27315356)

  • 1. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
    Lim SH; Sun JM; Choi YL; Kim HR; Ahn S; Lee JY; Lee SH; Ahn JS; Park K; Kim JH; Cho BC; Ahn MJ
    Cancer; 2016 Oct; 122(19):3024-31. PubMed ID: 27315356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
    Göke F; Franzen A; Menon R; Goltz D; Kirsten R; Boehm D; Vogel W; Göke A; Scheble V; Ellinger J; Gerigk U; Fend F; Wagner P; Schroeck A; Perner S
    Chest; 2012 Oct; 142(4):1020-1026. PubMed ID: 22499828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
    Lim SM; Chung WY; Nam KH; Kang SW; Lim JY; Kim HG; Shin SH; Sun JM; Kim SG; Kim JH; Kang CW; Kim HR; Cho BC
    Eur J Cancer; 2015 Aug; 51(12):1588-95. PubMed ID: 26070683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
    Kim HR; Kim DJ; Kang DR; Lee JG; Lim SM; Lee CY; Rha SY; Bae MK; Lee YJ; Kim SH; Ha SJ; Soo RA; Chung KY; Kim JH; Lee JH; Shim HS; Cho BC
    J Clin Oncol; 2013 Feb; 31(6):731-7. PubMed ID: 23182986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
    Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
    Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.
    Tran TN; Selinger CI; Kohonen-Corish MRJ; McCaughan BC; Kennedy CW; O'Toole SA; Cooper WA
    Lung Cancer; 2013 Sep; 81(3):462-467. PubMed ID: 23806793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
    Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE
    Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma.
    Craddock KJ; Ludkovski O; Sykes J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2013 Nov; 8(11):1371-7. PubMed ID: 24077455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.
    Cihoric N; Savic S; Schneider S; Ackermann I; Bichsel-Naef M; Schmid RA; Lardinois D; Gugger M; Bubendorf L; Zlobec I; Tapia C
    Br J Cancer; 2014 Jun; 110(12):2914-22. PubMed ID: 24853178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR1 amplification in squamous cell carcinoma of the lung.
    Heist RS; Mino-Kenudson M; Sequist LV; Tammireddy S; Morrissey L; Christiani DC; Engelman JA; Iafrate AJ
    J Thorac Oncol; 2012 Dec; 7(12):1775-1780. PubMed ID: 23154548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR1 Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status.
    Monaco SE; Rodriguez EF; Mahaffey AL; Dacic S
    Am J Clin Pathol; 2016 Jan; 145(1):55-61. PubMed ID: 26712871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.